The experience to date with HER2-targeting agents has revealed a degree of complexity with this amplified oncogene that sets it apart from oncogenes activated through gene mutation or fusion events such as EGFR or Alk in lung cancers, Bcr-abl in leukemias, or BRAF in melanomas. This evidence concerns the gene BRAF and lung carcinoma.